SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Orbifloxacin Liquid Formulation

Version 3.6  Revision Date: 27.08.2021  SDS Number: 785871-00014  Date of last issue: 09.04.2021  Date of first issue: 28.06.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name : Orbifloxacin Liquid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture : Veterinary product

1.3 Details of the supplier of the safety data sheet
Company : MSD
Kilsheenlan
Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)
Reproductive toxicity, Category 2 H361d: Suspected of damaging the unborn child.
Specific target organ toxicity - repeated exposure, Category 2, Eye H373: May cause damage to organs through prolonged or repeated exposure if swallowed.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)
Hazard pictograms :

Signal word : Warning

Hazard statements :
H361d Suspected of damaging the unborn child.
H373 May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

Precautionary statements : Prevention:
P201 Obtain special instructions before use.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
**Hazardous components which must be listed on the label:**

Orbifloxacin

**2.3 Other hazards**

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### SECTION 3: Composition/information on ingredients

#### 3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No. EC-No. Index-No. Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Dermal irritation</strong> Repr. 2; H361d</td>
<td>&gt;= 3 - &lt; 10</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Skin Irrit. 2; H315 Eye Dam. 1; H318</td>
<td>&gt;= 1 - &lt; 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>specific concentration limit Eye Irrit. 2; H319 1 - &lt; 3 %</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Met. Corr.</strong> Met. Corr. 1; H290 Skin Corr. 1A; H314 Eye Dam. 1; H318 EUH014, EUH071</td>
<td>&gt;= 1 - &lt; 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>specific concentration limit Skin Corr. 1A; H314</td>
<td></td>
</tr>
</tbody>
</table>
SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks: Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.
SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media:
- None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting:
- Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides
- Metal oxides

5.3 Advice for firefighters

Special protective equipment for firefighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions:
- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g. by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up:
- Soak up with inert absorbent material.
- For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can
be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation : Use only with adequate ventilation.
Advice on safe handling : Do not breathe mist or vapours.
: Do not swallow.
: Avoid contact with eyes.
: Avoid prolonged or repeated contact with skin.
: Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
: Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
: The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations.
Advice on common storage : Do not store with the following product types:
: Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available
SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propylene glycol</td>
<td>57-55-6</td>
<td>OELV - 8 hrs (TWA) (particles)</td>
<td>10 mg/m3</td>
<td>IE OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OELV - 8 hrs (TWA) (total (vapour and particles))</td>
<td>150 ppm 470 mg/m3</td>
<td>IE OEL</td>
</tr>
<tr>
<td>Orbifloxacin</td>
<td>113617-63-3</td>
<td>TWA</td>
<td>0.2 mg/m3 (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Silicon dioxide</td>
<td>7631-86-9</td>
<td>OELV - 8 hrs (TWA) (Respirable dust)</td>
<td>2.4 mg/m3 (Silica)</td>
<td>IE OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OELV - 8 hrs (TWA) (inhalable dust)</td>
<td>6 mg/m3 (Silica)</td>
<td>IE OEL</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>1310-73-2</td>
<td>OELV - 15 min (STEL)</td>
<td>2 mg/m3</td>
<td>IE OEL</td>
</tr>
</tbody>
</table>

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propylene glycol</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>10 mg/m3</td>
</tr>
<tr>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>168 mg/m3</td>
<td></td>
</tr>
<tr>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>10 mg/m3</td>
<td></td>
</tr>
<tr>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>50 mg/m3</td>
<td></td>
</tr>
<tr>
<td>Silicon dioxide</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>4 mg/m3</td>
</tr>
<tr>
<td>Lactic acid</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>592 mg/m3</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Acute local effects</td>
<td>592 mg/m3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>296 mg/m3</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>1 mg/m3</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>1 mg/m3</td>
</tr>
</tbody>
</table>

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propylene glycol</td>
<td>Fresh water</td>
<td>260 mg/l</td>
</tr>
<tr>
<td></td>
<td>Freshwater - intermittent</td>
<td>183 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>26 mg/l</td>
</tr>
</tbody>
</table>
8.2 Exposure controls

**Engineering measures**
Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Laboratory operations do not require special containment.

**Personal protective equipment**

- **Eye protection**: Wear safety glasses with side shields or goggles.
  If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
  Wear a face shield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

- **Hand protection**
  **Material**: Chemical-resistant gloves

- **Skin and body protection**: Work uniform or laboratory coat.

- **Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
  Equipment should conform to I.S. EN 14387
  **Filter type**: Combined particulates and organic vapour type (A-P)

**SECTION 9: Physical and chemical properties**

**9.1 Information on basic physical and chemical properties**

- **Physical state**: suspension
- **Colour**: light brown
- **Odour**: odourless
- **Odour Threshold**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flammability (solid, gas)**: Not applicable
- **Flammability (liquids)**: No data available
- **Upper explosion limit / Upper flammability limit**: No data available
- **Lower explosion limit / Lower flammability limit**: No data available
Orbifloxacin Liquid Formulation

flammmability limit

Flash point : No data available
Auto-ignition temperature : No data available
Decomposition temperature : No data available
pH : No data available
Viscosity
   Viscosity, kinematic : No data available
Solubility(ies)
   Water solubility : No data available
Partition coefficient: n-octanol/water : No data available
Vapour pressure : No data available
Relative density : No data available
Density : No data available
Relative vapour density : No data available
Particle characteristics
   Particle size : No data available

9.2 Other information

Explosives : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Evaporation rate : No data available
Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid : None known.
Section 10: Incompatible materials

Materials to avoid: Oxidizing agents

Section 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Components:

Orbifloxacin:
- Acute oral toxicity: LD50 (Rat): > 3,000 mg/kg
  Remarks: No mortality observed at this dose.
- LD50 (Mouse): > 2,000 mg/kg
  Remarks: No mortality observed at this dose.
- LD50 (Dog): > 600 mg/kg
  Symptoms: Vomiting
  Remarks: No mortality observed at this dose.

Acute inhalation toxicity: Remarks: No data available

Acute dermal toxicity: Remarks: No data available

Acute toxicity (other routes of administration):
- LD50 (Rat): > 200 mg/kg
  Application Route: Intramuscular
  LD50 (Mouse): 500 mg/kg
  Application Route: Intramuscular
  LD50 (Rat): 233 mg/kg
  Application Route: Intravenous
  LD50 (Mouse): 250 mg/kg
  Application Route: Intravenous

Lactic acid:
- Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
  Remarks: Based on data from similar materials
- Acute inhalation toxicity: LC50 (Rat): > 5 mg/l
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Orbifloxacin Liquid Formulation

Version 3.6  Revision Date: 27.08.2021  SDS Number: 785871-00014  Date of last issue: 09.04.2021

Date of first issue: 28.06.2016

Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Remarks: Based on data from similar materials

Acute dermal toxicity:
LD50 (Rabbit): > 2,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity
Remarks: Based on data from similar materials

Sodium hydroxide:
Acute inhalation toxicity:
Assessment: Corrosive to the respiratory tract.

Skin corrosion/irritation
Not classified based on available information.

Product:
Species: Rabbit
Result: No skin irritation

Components:
Orbifloxacin:
Species: Rabbit
Method: Draize Test
Result: No skin irritation

Lactic acid:
Species: Rabbit
Result: Skin irritation
Remarks: Based on data from similar materials

Sodium hydroxide:
Result: Corrosive after 3 minutes or less of exposure

Serious eye damage/eye irritation
Not classified based on available information.

Product:
Species: Rabbit
Result: Mild eye irritation

Components:
Orbifloxacin:
Species: Rabbit
Method: Draize Test
Result: Mild eye irritation
Lactic acid:
Species: Chicken eye
Remarks: Based on data from similar materials
Result: Irreversible effects on the eye

Sodium hydroxide:
Result: Irreversible effects on the eye
Remarks: Based on skin corrosivity.

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Product:
Test Type: Magnusson-Kligman-Test
Exposure routes: Dermal
Species: Guinea pig
Result: Not a skin sensitizer.

Components:

Orbifloxacin:
Test Type: Maximisation Test
Exposure routes: Dermal
Species: Guinea pig
Result: Not a skin sensitizer.

Lactic acid:
Test Type: Buehler Test
Exposure routes: Skin contact
Species: Guinea pig
Result: negative
Remarks: Based on data from similar materials

Sodium hydroxide:
Test Type: Human repeat insult patch test (HRIPT)
Exposure routes: Skin contact
Result: negative

Germ cell mutagenicity
Not classified based on available information.

Components:

Orbifloxacin:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Genotoxicity in vivo

**Result:** equivocal

**Test Type:** Mouse Lymphoma
**Result:** positive

**Test Type:** Chromosomal aberration
**Test system:** Human lymphocytes
**Result:** positive

**Genotoxicity in vivo**
**Test Type:** Micronucleus test
**Species:** Mouse
**Cell type:** Bone marrow
**Application Route:** Intraperitoneal injection
**Result:** negative

**Test Type:** unscheduled DNA synthesis assay
**Species:** Rat
**Cell type:** Liver cells
**Application Route:** Oral
**Result:** negative

**Germ cell mutagenicity- Assessment**
**Weight of evidence does not support classification as a germ cell mutagen.**

**Lactic acid:**

**Genotoxicity in vitro**
**Test Type:** Bacterial reverse mutation assay (AMES)
**Method:** OECD Test Guideline 471
**Result:** negative
**Remarks:** Based on data from similar materials

**Test Type:** In vitro mammalian cell gene mutation test
**Method:** OECD Test Guideline 476
**Result:** negative
**Remarks:** Based on data from similar materials

**Test Type:** Chromosome aberration test in vitro
**Method:** OECD Test Guideline 473
**Result:** negative
**Remarks:** Based on data from similar materials

**Carcinogenicity**
**Not classified based on available information.**

**Components:**

**Orbifloxacin:**
**Species**: Rat
**Application Route**: Oral
**Exposure time**: 2 Years
**NOAEL**: 200 mg/kg body weight
**Result**: negative

**Species**: Mouse
Orbifloxacin Liquid Formulation

Application Route : Oral
Exposure time : 2 Years
NOAEL : 200 mg/kg body weight
Result : negative

Lactic acid:
Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative
Remarks : Based on data from similar materials

Reproductive toxicity
Suspected of damaging the unborn child.

Components:

Orbifloxacin:
Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity - Parent: NOAEL: 50 mg/kg body weight
Early Embryonic Development: NOAEL: 50 mg/kg body weight
Result: No adverse effects

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Embryo-foetal toxicity: LOAEL: 333 mg/kg body weight
Result: No teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
General Toxicity Maternal: NOAEL: 20 mg/kg body weight
Embryo-foetal toxicity: NOAEL: 60 mg/kg body weight
Result: No effects on early embryonic development, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain

Test Type: Development
Species: Dog
Application Route: Oral
Developmental Toxicity: LOAEL: 2.5 mg/kg body weight
Result: Effects on postnatal development, Skeletal malformations

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.
Lactic acid:
Effects on foetal development: Test Type: Embryo-foetal development
Species: Mouse
Application Route: Ingestion
Result: negative

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

Product:
Target Organs: Eye
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Product:

Species: Dog
NOAEL: 22.5 mg/kg
LOAEL: 37.5 mg/kg
Application Route: Oral
Exposure time: 30 Days
Symptoms: Gastrointestinal disturbance

Species: Dog
NOAEL: 75 mg/kg
LOAEL: 75 mg/kg
Application Route: Oral
Exposure time: 10 Days
Symptoms: Salivation, Gastrointestinal disturbance, Vomiting

Species: Cat
NOAEL: 45 mg/kg
Application Route: Oral
Exposure time: 30 Days
Target Organs: Eye
Symptoms: Salivation, Lacrymation, Gastrointestinal disturbance, Liver disorders

Components:

Orbifloxacin:
Species: Rat
NOAEL: 20 mg/kg
LOAEL: 80 mg/kg
Application Route: Oral
Exposure time: 3 Months
Target Organs: Testis, Liver, Kidney, spleen
# Orbifloxacin Liquid Formulation

<table>
<thead>
<tr>
<th>Species</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>80 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>250 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>3 Months</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Juvenile dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>50 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>250 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>14 Days</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Heart, Bone</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Gastrointestinal disturbance</td>
</tr>
<tr>
<td>Remarks</td>
<td>mortality observed</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Juvenile dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>2 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>3 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>90 Days</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Bone</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>37.5 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>30 Days</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Cat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>7.5 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>22.5 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>1 Months</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Gastrointestinal disturbance</td>
</tr>
</tbody>
</table>

## Lactic acid:

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>&gt; 100 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Exposure time</td>
<td>13 Weeks</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>886 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Skin contact</td>
</tr>
<tr>
<td>Exposure time</td>
<td>13 Weeks</td>
</tr>
</tbody>
</table>

## Aspiration toxicity

Not classified based on available information.
11.2 Information on other hazards

Endocrine disrupting properties

Product:
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:
Orbifloxacin:
Ingestion: Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash
Remarks: May cause photosensitisation.

SECTION 12: Ecological information

12.1 Toxicity

Components:
Lactic acid:
Toxicity to fish: LC50 (Danio rerio (zebra fish)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants: ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

NOEC (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms: EC50: > 10 - 100 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209
Remarks: Based on data from similar materials
12.2 Persistence and degradability

**Components:**

**Lactic acid:**
- Biodegradability: Result: Not readily biodegradable.
- Remarks: Based on data from similar materials

12.3 Bioaccumulative potential

**Components:**

**Lactic acid:**
- Partition coefficient: n-octanol/water: log Pow: -0.62

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

**Product:**
**Assessment:** This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

**Product:**
**Assessment:** The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

**Product:**
- Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

**Contaminated packaging:**
- Empty containers should be taken to an approved waste handling site for recycling or disposal.
- If not otherwise specified: Dispose of as unused product.
SECTION 14: Transport information

14.1 UN number or ID number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Maritime transport in bulk according to IMO instruments
Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Conditions of restriction for the following entries should be considered:
Number on list 3
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable
REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:
AICS : not determined
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Orbifloxacin Liquid Formulation

Date of last issue: 09.04.2021
Date of first issue: 28.06.2016

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H290 : May be corrosive to metals.
H314 : Causes severe skin burns and eye damage.
H315 : Causes skin irritation.
H318 : Causes serious eye damage.
H361d : Suspected of damaging the unborn child.
EUH014 : Reacts violently with water.
EUH071 : Corrosive to the respiratory tract.

Full text of other abbreviations

Eye Dam. : Serious eye damage
Met. Corr. : Corrosive to metals
Repr. : Reproductive toxicity
Skin Corr. : Skin corrosion
Skin Irrit. : Skin irritation
IE OEL : Ireland. List of Chemical Agents and Occupational Exposure Limit Values - Schedule 1
IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)
IE OEL / OELV - 15 min (STEL) : Occupational exposure limit value (15-minute reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -
International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information


Classification of the mixture:

<table>
<thead>
<tr>
<th>Classification procedure:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>H361d</td>
<td>Calculation method</td>
</tr>
<tr>
<td>H373</td>
<td>Based on product data or assessment</td>
</tr>
</tbody>
</table>

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.